Drug intelligence / Profile preview

DWC202205

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202205 is an orally administered small molecule drug candidate developed by Daewoong Pharmaceutical. Its mechanism of action has not been disclosed, and it is considered a new molecular entity. The drug has been evaluated in phase 1 clinical trials, primarily for safety and pharmacokinetic/pharmacodynamic interactions in healthy adult volunteers. No approved indications or therapeutic areas have been reported, and the active indication remains undisclosed[1][2][5].

Beyond the preview

Go deeper on DWC202205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202205.

Explore the full profile